Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | NPC1 | O15118 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | AHR | P35869 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | USP8 | P40818 | 3/20 | 0.60 |
| ▸ | USP7 | Q93009 | 1/20 | 0.60 |
| ▸ | USP47 | Q96K76 | 1/20 | 0.60 |
| ▸ | CDC25B | P30305 | 1/20 | 0.48 |
| ▸ | PTPRC | P08575 | 2/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1705356 | 0.93 | RAB9A (0.88) | RAB9AMAPTSMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL2681287 | 0.85 | RAB9A (0.74) | RAB9AMAPTSMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL2489961 | 0.85 | MAPT (0.73) | RAB9AMAPTSMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL17333584 | 0.83 | MAPT (0.70) | RAB9AMAPTSMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL14572522 | 0.82 | RAB9A (0.69) | RAB9AMAPTSMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL14532729 | 0.82 | RAB9A (0.73) | RAB9AMAPTSMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL16869836 | 0.82 | RAB9A (0.68) | RAB9AMAPTSMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL21226345 | 0.82 | RAB9A (0.68) | RAB9AMAPTSMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL14572513 | 0.82 | RAB9A (1.00) | RAB9AMAPTSMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL6254319 | 0.82 | RAB9A (1.00) | RAB9AMAPTSMN1; SMN2NPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160106743-A1 | TOPOISOMERASE II POISONS AND METHODS OF MAKING AND USING SAME | THE UNIVERSITY OF ROCHESTER (US) | 2016-04-21 | — | — | US | claimed |
| US-4082750-A | PHOTOSENSITIZERS, NITRATION | RICOH CO., LTD. (JA) | 1978-04-04 | — | — | US | claimed |
| US-20230265058-A1 | CARBOXYLIC ACID OR CARBOXYLIC ACID ESTER COMPOUND HAVING FUSED-RING STRUCTURE, METHOD FOR PRODUCING THE SAME, AND USE OF COMPOUND | FUJIFILM CORPORATION (JP) | 2023-08-24 | — | — | US | disclosed |
| US-20230265058-A1 | CARBOXYLIC ACID OR CARBOXYLIC ACID ESTER COMPOUND HAVING FUSED-RING STRUCTURE, METHOD FOR PRODUCING THE SAME, AND USE OF COMPOUND | FUJIFILM CORPORATION (JP) | 2023-08-24 | — | — | US | disclosed |
| WO-2023145663-A1 | SOLVATE AND METHOD FOR MANUFACTURING SOLVATE | 富士フイルム株式会社 | 2023-08-03 | — | — | WO | disclosed |
| US-20230183406-A1 | COMPOUND, CURABLE RESIN COMPOSITION, CURED PRODUCT, OPTICAL MEMBER, AND LENS | FUJIFILM CORPORATION (JP) | 2023-06-15 | — | — | US | disclosed |
| US-11370744-B2 | Compound, curable composition, cured product, optical member, and lens | FUJIFILM CORPORATION (JP) | 2022-06-28 | — | — | US | disclosed |
| US-20210299123-A1 | SURVIVIN-TARGETING ANTI-TUMOR AGENTS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-09-30 | — | — | US | disclosed |
| US-20200181061-A1 | COMPOUND, CURABLE COMPOSITION, CURED PRODUCT, OPTICAL MEMBER, AND LENS | FUJIFILM CORPORATION (JP) | 2020-06-11 | — | — | US | disclosed |
| EP-3261759-B1 | SELF-HEALING CAPACITOR AND METHODS OF PRODUCTION THEREOF | CAPACITOR SCIENCES INC (US) | 2020-05-06 | — | — | EP | disclosed |
| US-20200131309-A1 | PHASE DIFFERENCE FILM | FUJIFILM CORPORATION (JP) | 2020-04-30 | — | — | US | disclosed |
| US-20090161037-A1 | Backlight Module and Liquid Crystal Display Incorporating the Same | CRYSOPTIX KK (JP) | 2009-06-25 | — | — | US | disclosed |
| US-20090161037-A1 | Backlight Module and Liquid Crystal Display Incorporating the Same | CRYSOPTIX KK (JP) | 2009-06-25 | — | — | US | disclosed |
| WO-2009037565-A2 | COLOUR LIQUID CRYSTAL DISPLAY AND PATTERNED COMPENSATION PANEL | CRYSOPTIX K.K. (GB) | 2009-03-26 | — | — | WO | disclosed |
| WO-2008142635-A2 | COMPENSATED IN-PLANE SWITCHING MODE LIQUID CRYSTAL DISPLAY | CRYSOPTIX KK (GB) | 2008-11-27 | — | — | WO | disclosed |
| WO-2007141025-A2 | LIQUID CRYSTAL DISPLAY OPERATING IN A VERTICALLY ALIGNED MODE | CRYSOPTIX K.K. (JP) | 2007-12-13 | — | — | WO | disclosed |
| WO-2007122389-A2 | BACKLIGHT MODULE AND LIQUID CRYSTAL DISPLAY INCORPORATING THE SAME | CRYSOPTIX K.K. (JP) | 2007-11-01 | — | — | WO | disclosed |
| US-4148638-A | ELECTROPHOTOGRAPHIC PLATE | RICOH CO., LTD. (JP) | 1979-04-10 | — | — | US | disclosed |
| US-4082750-A | PHOTOSENSITIZERS, NITRATION | RICOH CO., LTD. (JA) | 1978-04-04 | — | — | US | disclosed |
| US-4082750-A | PHOTOSENSITIZERS, NITRATION | RICOH CO., LTD. (JA) | 1978-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183406-A1 | COMPOUND, CURABLE RESIN COMPOSITION, CURED PRODUCT, OPTICAL MEMBER, AND LENS | POLR1A, RAD51, POLR2A | RAB9A 3643/4885MAPT 419/4885SMN1; SMN2 587/4885 |
| US-20230265058-A1 | CARBOXYLIC ACID OR CARBOXYLIC ACID ESTER COMPOUND HAVING FUSED-RING STRUCTURE, METHOD FOR PRODUCING THE SAME, AND USE OF COMPOUND | SPG11, HAT1, ASS1 | RAB9A 3033/4885MAPT 1976/4885SMN1; SMN2 567/4885 |
| US-20200181061-A1 | COMPOUND, CURABLE COMPOSITION, CURED PRODUCT, OPTICAL MEMBER, AND LENS | CRYZ, CRYAA, WDR12 | RAB9A 3444/4885MAPT 1212/4885SMN1; SMN2 2295/4885 |
| US-20210299123-A1 | SURVIVIN-TARGETING ANTI-TUMOR AGENTS AND USES THEREOF | XIAP, BIRC5, TP53 | RAB9A 2145/4885MAPT 3150/4885SMN1; SMN2 3055/4885 |
| US-20160106743-A1 | TOPOISOMERASE II POISONS AND METHODS OF MAKING AND USING SAME | TOP2A, TOP2B, TOP1 | RAB9A 3488/4885MAPT 3723/4885SMN1; SMN2 1196/4885 |
| US-11370744-B2 | Compound, curable composition, cured product, optical member, and lens | CRYZ, CRYAA, WDR12 | RAB9A 3444/4885MAPT 1212/4885SMN1; SMN2 2295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.